首页> 外文期刊>The lancet oncology >Tumour-cell fusion as a source of myeloid traits in cancer.
【24h】

Tumour-cell fusion as a source of myeloid traits in cancer.

机译:肿瘤细胞融合是癌症髓样特征的来源。

获取原文
获取原文并翻译 | 示例
           

摘要

Malignant cells express molecular pathways that are also expressed by myeloid cells. Such behaviour is associated with loss of homotypic adhesion between cells, changes in the cellular matrix, induction of angiogenesis, motility, chemotaxis, and several immune-signalling pathways. The overlap between malignant cells and myeloid cells could be explained by one mechanism: fusion of myeloid cells and tumour cells, as noted in animal studies and in two patients with renal-cell carcinoma who underwent bone-marrow transplantation. An overlapping trait in these cells is their glycosylation patterns: hybrids have high expression of N-terminal glycosylation and beta1,6-branched oligosaccharides. In macrophages and cancer cells, these structures have a role in motility and systemic migration; in cancer, they are associated with metastasis and poor prognosis. In addition to myeloid traits, fusion might contribute to aneuploidy and plasticity in cancer. Understanding metastatic cells as myeloid-tumour hybrids suggests new strategies for diagnosis, treatment, and prevention of malignant disease.
机译:恶性细胞表达也由髓样细胞表达的分子途径。这种行为与细胞之间同型粘附的丧失,细胞基质的改变,血管生成的诱导,运动性,趋化性和几种免疫信号途径有关。恶性细胞与髓样细胞之间的重叠可以用一种机制来解释:如动物研究和两名接受骨髓移植的肾细胞癌患者所述,髓样细胞与肿瘤细胞融合。这些细胞的重叠特征是它们的糖基化模式:杂种具有高表达的N末端糖基化和β1,6-支链寡糖。在巨噬细胞和癌细胞中,这些结构在运动和全身迁移中起作用。在癌症中,它们与转移和预后不良有关。除了骨髓性状外,融合还可能导致癌症的非整倍性和可塑性。将转移细胞理解为骨髓-肿瘤杂交体,为诊断,治疗和预防恶性疾病提出了新的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号